NO20001886L - Stabile, krystallinske salter av 5-metyltetrahydrofolsyre og fremgangsmÕte til fremstilling derav - Google Patents

Stabile, krystallinske salter av 5-metyltetrahydrofolsyre og fremgangsmÕte til fremstilling derav

Info

Publication number
NO20001886L
NO20001886L NO20001886A NO20001886A NO20001886L NO 20001886 L NO20001886 L NO 20001886L NO 20001886 A NO20001886 A NO 20001886A NO 20001886 A NO20001886 A NO 20001886A NO 20001886 L NO20001886 L NO 20001886L
Authority
NO
Norway
Prior art keywords
preparation
crystalline salts
stable crystalline
methyltetrahydrofolic acid
methyl
Prior art date
Application number
NO20001886A
Other languages
English (en)
Other versions
NO325495B1 (no
NO20001886D0 (no
Inventor
Hans Rudolf Mueller
Rudolf Moser
Thomas Egger
Original Assignee
Eprova Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4193016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20001886(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eprova Ag filed Critical Eprova Ag
Publication of NO20001886D0 publication Critical patent/NO20001886D0/no
Publication of NO20001886L publication Critical patent/NO20001886L/no
Publication of NO325495B1 publication Critical patent/NO325495B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
NO20001886A 1999-04-15 2000-04-12 Stabile, krystallinske salter av 5-metyltetrahydrofolsyre og fremgangsmate til fremstilling derav NO325495B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH00695/99A CH693905A5 (de) 1999-04-15 1999-04-15 Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.

Publications (3)

Publication Number Publication Date
NO20001886D0 NO20001886D0 (no) 2000-04-12
NO20001886L true NO20001886L (no) 2000-10-16
NO325495B1 NO325495B1 (no) 2008-05-19

Family

ID=4193016

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001886A NO325495B1 (no) 1999-04-15 2000-04-12 Stabile, krystallinske salter av 5-metyltetrahydrofolsyre og fremgangsmate til fremstilling derav

Country Status (19)

Country Link
US (1) US6441168B1 (no)
EP (5) EP1044975B1 (no)
JP (4) JP5202774B2 (no)
KR (2) KR100774012B1 (no)
CN (1) CN1154648C (no)
AT (2) ATE496052T1 (no)
AU (1) AU782641B2 (no)
CA (1) CA2305926C (no)
CH (1) CH693905A5 (no)
CY (2) CY1109874T1 (no)
DE (2) DE50015815D1 (no)
DK (4) DK2194057T3 (no)
ES (3) ES2374369T3 (no)
HU (1) HU229423B1 (no)
NO (1) NO325495B1 (no)
PT (4) PT2192120E (no)
RU (1) RU2265605C2 (no)
TW (1) TWI285205B (no)
ZA (1) ZA200001851B (no)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
EP1349554A2 (en) * 2000-12-14 2003-10-08 Tufts University Compositions and methods for treating an arthritic condition
ES2905305T4 (es) 2003-11-17 2022-07-13 Biomarin Pharm Inc Tratamiento de la fenilcetonuria con BH4
ATE498401T1 (de) * 2004-09-15 2011-03-15 Nipro Corp Wässrige, stabile (6s)-folinsäurelösung zur injektion
WO2006063215A2 (en) * 2004-12-08 2006-06-15 Biomarin Pharmaceutical Inc. Methods and compositions for the treatment of pulmonary hypertension of the newborn
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
CN101489563A (zh) 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
DE112007001600A5 (de) * 2006-07-06 2009-04-30 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
EP1891959A1 (de) * 2006-08-14 2008-02-27 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
US8617597B2 (en) * 2006-07-06 2013-12-31 Bayer Intellectual Property Gmbh Pharmaceutical composition containing a tetrahydrofolic acid
CH698729B1 (de) 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
EP2027855A1 (de) 2007-08-24 2009-02-25 Bayer Schering Pharma AG Verwendung von Gestagenen in Kombination mit (6S)5-Methyltetrahydrofolat zur Therapie der Endometriose mit gleichzeitiger Verminderung von Therapie-Nebenwirkungen sowie der Verminderung des Risikos angeborener Fehlbildungen bei Eintritt einer Gravidität
US20090060997A1 (en) * 2007-08-27 2009-03-05 Christian Seitz Process for producing a pharmaceutical preparation for therapeutic treatment of endometriosis containing a combination of a gestagen and (6s)-5-methyltetrahydrofolate
WO2009101021A2 (en) * 2008-02-13 2009-08-20 Bayer Schering Pharma Aktiengesellschaft Estradiol-containing drug delivery system
JP2011511816A (ja) * 2008-02-13 2011-04-14 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 安定化効果を有する薬物送達システム
PL2245032T3 (pl) * 2008-02-20 2015-08-31 Gnosis Spa Foliany, ich kompozycje i zastosowania
AU2010271178B2 (en) 2009-07-10 2015-10-22 Linzy O. Scott Iii Methods and compositions for treating thyroid-related medical conditions with reduced folates
UY32836A (es) 2009-08-12 2011-03-31 Bayer Schering Pharma Ag Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
AU2011215669B2 (en) 2010-02-12 2015-06-04 HedoniaUSA, Inc. Compositions and methods for treating depression
WO2012074496A1 (en) * 2010-12-03 2012-06-07 Kocak Farma Ilac Ve Kimya San. A.S A new method for producing antifolate agents having glutamic acid part in their structure
CN102516247A (zh) * 2010-12-15 2012-06-27 连云港金康医药科技有限公司 A型l-5-甲基四氢叶酸钙盐多晶型及其制备方法
EP2502625A1 (en) 2011-03-21 2012-09-26 GMT Fine Chemicals SA Process for the preparation of crystalline levofolinic acid
CN102702200B (zh) * 2012-04-25 2014-11-12 连云港金康和信药业有限公司 (6rs)-5-甲基四氢叶酸钙盐晶型及其制备方法
CN102584826B (zh) * 2012-01-20 2015-04-29 连云港金康医药科技有限公司 (6s)-5-甲基四氢叶酸盐晶型及其制备方法
IN2014DN06942A (no) * 2012-01-20 2015-04-10 Lianyungang Jinkang Hexin Pharmaceutical Co Ltd
CN102775407B (zh) * 2012-01-20 2015-08-05 连云港金康医药科技有限公司 稳定的无定型5-甲基四氢叶酸盐及其制备方法
WO2013163917A1 (zh) * 2012-04-13 2013-11-07 连云港金康和信药业有限公司 化合物jk12a及其制备
CN103450202B (zh) * 2012-06-04 2015-07-01 南京莱因医药科技有限公司 L-5-甲基四氢叶酸与有机碱加成盐的方法
CN103664945B (zh) * 2012-09-07 2016-01-20 南京莱因医药科技有限公司 L-5-甲基四氢叶酸氨基酸盐的制备方法
CN103694239B (zh) * 2012-09-27 2016-12-21 上海科胜药物研发有限公司 一种5‑甲基‑（6s）‑四氢叶酸晶型a及其制备方法
EP2781214A1 (en) * 2013-03-22 2014-09-24 Chemo Research, S.L. Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)
JP2016525576A (ja) * 2013-07-29 2016-08-25 アデア ファーマシューティカルズ，インコーポレイテッド 安定化された修飾放出型葉酸誘導体組成物、その治療用途および製造方法
US20160053281A1 (en) 2013-08-15 2016-02-25 The University Court Of The University Of Edinburgh Enhanced Expression Of RNA Vectors
US9629846B1 (en) 2013-11-14 2017-04-25 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
US9492421B1 (en) 2013-11-14 2016-11-15 Argent Development Group, Llc Nutritional supplements for treatment of iron deficiency anemia
EP2878600B1 (en) 2013-12-02 2018-06-27 Cerbios-Pharma S.A. Stable complexes of an alkaline earth metal salt of N5-methyl-tetrahydrofolic acid and a polyol
CN103980279B (zh) * 2014-04-16 2016-07-06 悦康药业集团有限公司 一种甲氨蝶呤化合物及注射用甲氨蝶呤
WO2015193778A1 (en) 2014-06-16 2015-12-23 Mylan Laboratories Ltd. Crystalline form of levomefolate calcium
CN104490887A (zh) * 2014-09-04 2015-04-08 连云港金康和信药业有限公司 (6s)-5-甲基-四氢叶酸钙盐的稳定药物组合物
CN105524066B (zh) 2014-09-04 2017-06-27 连云港金康和信药业有限公司 (6s)‑5‑甲基四氢叶酸或其盐组合物及其制备和应用
CN104225609B (zh) 2014-09-20 2018-05-18 中国药科大学 一种炎症靶向的中性粒细胞递药系统及其应用
WO2016135707A1 (en) 2015-02-27 2016-09-01 Nestec S.A. Diagnosis of major depressive disorder, mild cognitive impairment, and alzheimer's disease and other neurologic and psychiatric disorders
WO2016185413A1 (en) 2015-05-20 2016-11-24 Nestec S.A. Modified release formulations
CN107698591A (zh) * 2015-09-25 2018-02-16 上海华理生物医药有限公司 (6s)-5-甲基四氢叶酸锌盐晶型及其制备方法
DE202015105351U1 (de) 2015-10-09 2016-01-07 Apotheke am Schlossplatz Inh. Mario Ganster e.K. Diätetische Zusammensetzung
KR101712807B1 (ko) 2015-10-19 2017-03-07 오인숙 스테인레스 빔 제조장치
CN105237539A (zh) * 2015-10-29 2016-01-13 上海应用技术学院 A晶型(6s)-5-甲基四氢叶酸锌盐及其制备方法
CN107304212A (zh) * 2016-04-21 2017-10-31 常州爱诺新睿医药技术有限公司 一种无定型l-5-甲基四氢叶酸氨基酸盐及其制备方法
WO2018144088A1 (en) 2016-11-03 2018-08-09 Alexander Vuckovic, M.D., Llc Compositions and methods for treating depression
US11185545B2 (en) 2017-03-31 2021-11-30 Merck Patent Gmbh Crystalline monosodium salt of 5-methyl-(6S)-tetrahydrofolic acid
EP3601289A1 (en) 2017-03-31 2020-02-05 Merck Patent GmbH Crystalline binary sodium salts of 5-methyl-(6s)-tetrahydrofolic acid with organic bases
EP3609895A1 (en) * 2017-03-31 2020-02-19 Merck Patent GmbH Crystalline sodium salt of 5-methyl-(6s)-tetrahydrofolic acid
EP3461826A1 (en) 2017-09-29 2019-04-03 Aprofol AG Multifunctional folate salts
EP3818048B1 (en) * 2018-07-06 2023-09-20 Merck Patent GmbH Crystalline salt comprising 5-methyl-(6s)-tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine
US20210277006A1 (en) * 2018-07-06 2021-09-09 Merck Patent Gmbh Crystalline salts of 5-methyl-(6s)-tetrahydrofolic acid and amino ethyl esters
EP3817813B1 (en) * 2018-07-06 2023-09-20 Merck Patent GmbH Crystalline salts of 5-methyl-(6s)-tetrahydrofolic acid and l-leucine ethyl ester
US20210269444A1 (en) * 2018-07-06 2021-09-02 Merck Patent Gmbh Crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester
EP3817814B1 (en) * 2018-07-06 2023-09-20 Merck Patent GmbH Crystalline salts of 5-methyl-(6s)-tetrahydrofolic acid and l-valine ethyl ester
EP3646873A1 (en) 2018-10-31 2020-05-06 Aprofol AG Folate salts
EP3666260A1 (en) 2018-12-13 2020-06-17 Laboratorios Leon Farma SA Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof
US20230162351A1 (en) 2020-04-23 2023-05-25 National University Corporation Shiga University Of Medical Science Diagnosis assistance device, machine learning device, diagnosis assistance method, machine learning method, machine learning program, and alzheimers prediction program
EP4149437A1 (en) 2020-05-15 2023-03-22 Alfasigma S.p.A. Composition comprising methylfolate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1572137A (en) 1977-02-22 1980-07-23 Bioresearch Sas Del Dr Livio C Stable compositions for therapeutic use based on d,1-5-methyltetrahydrofolic acid and its salts
US5223500A (en) * 1977-02-22 1993-06-29 Bioresearch S.P.A. Stable pharmaceutical composition of alkaline or alkaline earth 5-methyl tetrahydrofolate
DE3821875C1 (no) 1988-06-29 1990-02-15 Eprova Ag, Forschungsinstitut, Schaffhausen, Ch
CH680731A5 (no) * 1990-04-12 1992-10-30 Sapec Fine Chemicals
CH681303A5 (no) 1991-01-16 1993-02-26 Eprova Ag
CH684270A5 (de) 1991-10-04 1994-08-15 Sapec Fine Chemicals Verfahren zur Herstellung von Erdalkalimetallsalzen von (6R)-N(10)-Formyl-5,6,7,8-tetrahydrofolsäure.
CH683261A5 (it) * 1991-10-10 1994-02-15 Applied Pharma Res Procedimento per la preparazione dell'acido metiltetraidrofolico nella forma (6(R,S)(-))N-5 e separazione del diastereoisomero attivo (6(S)(-))N-5) sotto forma di sali.
CH682664A5 (en) 1991-10-15 1993-10-29 Eprova Ag Stable salts of 5,10-methylene tetrahydrofolate.
CH682665A5 (de) 1991-10-29 1993-10-29 Sapec Fine Chemicals Verfahren zur Reinigung von rohen Erdalkalimetallsalzen von N(5)-Methyl-5,6,7,8-tetrahydrofolsäure.
DE4136921A1 (de) * 1991-11-11 1993-05-13 Knoll Ag Verfahren zur trennung von 5-methyl-tetrahydrofolsaeure
CH686672A5 (de) * 1992-12-01 1996-05-31 Cerbios Pharma Sa Verfahren zur Herstellung von (6S)-5,6,7,8-Tetrahydrofolsaeure.
CH686369A5 (de) * 1994-05-09 1996-03-15 Eprova Ag Stabile kristalline (6S)- und (6R)-Tetrahydrofolseure.
CH689831A5 (de) * 1995-11-07 1999-12-15 Eprova Ag Stabile kristalline Tetrahydrofolsaeure-Salze.
DK0877563T3 (da) 1996-01-31 2004-07-26 Univ South Alabama Levnedsmiddel- og vitaminpræparater, der indeholder den naturlige isomer af reducerede folater
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.

Also Published As

Publication number Publication date
JP5675758B2 (ja) 2015-02-25
KR20010014732A (ko) 2001-02-26
CY1109874T1 (el) 2014-09-10
JP2013047279A (ja) 2013-03-07
ES2374371T3 (es) 2012-02-16
CA2305926C (en) 2008-10-07
JP5675760B2 (ja) 2015-02-25
CN1154648C (zh) 2004-06-23
ZA200001851B (en) 2000-12-06
HU229423B1 (en) 2013-12-30
RU2265605C2 (ru) 2005-12-10
DK2189459T3 (da) 2011-04-18
JP2013047278A (ja) 2013-03-07
HUP0001560A2 (hu) 2001-04-28
PT2192120E (pt) 2012-01-16
ATE496052T1 (de) 2011-02-15
HU0001560D0 (en) 2000-06-28
PT1044975E (pt) 2010-03-09
ES2336190T3 (es) 2010-04-09
DK1044975T3 (da) 2010-03-22
EP1044975B1 (de) 2009-12-09
NO325495B1 (no) 2008-05-19
EP2189459A1 (de) 2010-05-26
KR100874368B1 (ko) 2008-12-16
EP2192120B1 (de) 2011-10-26
ES2374369T3 (es) 2012-02-16
DK2192120T3 (da) 2012-01-16
HUP0001560A3 (en) 2003-04-28
CA2305926A1 (en) 2000-10-15
JP2000327680A (ja) 2000-11-28
DE50015815D1 (de) 2010-01-21
KR20070062964A (ko) 2007-06-18
AU782641B2 (en) 2005-08-18
DE50016064D1 (de) 2011-03-03
EP1044975A1 (de) 2000-10-18
EP1695975A1 (de) 2006-08-30
NO20001886D0 (no) 2000-04-12
AU2768900A (en) 2000-10-19
CH693905A5 (de) 2004-04-15
PT2194057E (pt) 2012-01-16
JP2013047280A (ja) 2013-03-07
JP5202774B2 (ja) 2013-06-05
EP2194057A1 (de) 2010-06-09
ATE451372T1 (de) 2009-12-15
JP5675759B2 (ja) 2015-02-25
TWI285205B (en) 2007-08-11
EP2194057B1 (de) 2011-10-26
CY1111313T1 (el) 2015-08-05
DK2194057T3 (da) 2012-01-16
PT2189459E (pt) 2011-04-14
CN1277197A (zh) 2000-12-20
KR100774012B1 (ko) 2007-11-08
EP2189459B1 (de) 2011-01-19
EP2192120A1 (de) 2010-06-02
US6441168B1 (en) 2002-08-27

Similar Documents

Publication Publication Date Title
NO20001886L (no) Stabile, krystallinske salter av 5-metyltetrahydrofolsyre og fremgangsmÕte til fremstilling derav
WO2002009713A3 (de) Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
WO2002100860A3 (fr) Composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
CA2280447A1 (en) Pyrrolo¬1,2-a|pyrazine derivatives as 5ht1a ligands
ATE188699T1 (de) Stabile kristalline (6s)- und (6r)- tetrahydrofolsäure
WO2002030870A3 (de) Substituierte c-cyclohexylmethylamin-derivate
ATE399786T1 (de) 3-substituierte 3,4-dihydro-thieno 2,3-d pyrimidin-4-one-derivate, ihre herstellung und verwendung
WO2002083622A3 (en) Novel aminophenyl ketone derivatives
AU7492591A (en) Diastereoisomeric compounds derived from tetrahydrofolic acid, process for their preparation and use in the synthesis of diastereoisomers 6s and 6r of reduced folates
WO2001019826A3 (en) Triazolopyrimidine derivatives
ZA200305877B (en) Novel pyrazine derivatives or salts thereof, pharmaceutical composition containing the same, and production intermediates thereof.
ZA200201781B (en) Process for production of naphthyridine-3-carboxylic acid derivatives.
AU2001258200A1 (en) Synthetic derivatives of lunularic acid, medicaments containing said compounds, method for producing the lunularic acid derivatives and the use thereof
PL373247A1 (en) Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide
HUP0401617A3 (en) Process for the preparation of (r)- or (s)-aminocarnitine inner salt, the salts and derivatives thereof
TW353070B (en) Chloropyridylcarbonyl derivatives
MXPA03004632A (es) Klainetina y sus derivados, metodo para su produccion y su uso.
CY1112161T1 (el) Σταθερο κρυσταλλικο μετα ασβεστιου αλας toy 5-meθyλo-(6s)- τετραϋδροφολικου οξεος
IL160162A0 (en) Salts of substituted 1,2,3,4,-tetrahydroisoquinolie-2-carboxylic acid derivatives
UA85235C2 (ru) Кристаллический безводный арипипразол d, способ его получения, фармацевтическая композиция, содержащая кристаллический безводный арипипразол d, и способ ее получения
NO914068D0 (no) Diastereoisomeriske forbindelser utvunnet fra tetrahydrofolisk syre, fremgangsmaate for deres preparering og bruk i syntesen av diastereoisomerer 6s og 6r av reduserte salter
NO20023565D0 (no) Fremgangsmåte for fremstilling av 6-(4-klorfenyl)-2,2-dimetyl- 7-fenyl-2,3-dihydro-1H-pyrrolizin-5-yl-eddiksyre
AU2001280215A1 (en) Process for Production of Biopterin Compound

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0

MK1K Patent expired